Presentation Information
[29-53-pm1-07]Analysis of risk factors for early discontinuation of bevacizumab in patients with hepatocellular carcinoma receiving atezolizumab and bevacizumab treatment.
○Daisuke Kanai1, Yuki Kawarada1, Mari Iinuma1, Hiroyuki Mizoguchi1, Hiroaki Ikesue1 (1. Department of Hospital Pharmacy , Nagoya University Hospital)
Password required to view
Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.
The password will be emailed to those who have completed the registration.